中国[177Lu]Lu-DOTA-TATE治疗后的辐射暴露与防护建议
该研究在中国首次测量30例胃肠胰神经内分泌肿瘤(GEP-NENs)患者接受[177Lu]Lu-DOTA-TATE治疗期间的体外剂量率(EDR)及对护士和环境的辐射剂量(RD),通过双指数曲线拟合估算不同出院时间对公众的RD,并据此提出患者出院后与成人家庭成员、10岁以上儿童、3-10岁儿童及同事开始日常接触的最短时间建议。
要点
- 30例GEP-NENs患者中27例完成4周期[177Lu]Lu-DOTA-TATE治疗。
- 估算成人家庭成员、10岁以上儿童、3-10岁儿童及同事开始日常接触的最短时间分别为注射后至少24 h、48 h、144 h和192 h。
- 住院期间给药护士和病房环境累积剂量均远低于国家辐射剂量限值。
核心结论
- 该研究对接受[177Lu]Lu-DOTA-TATE治疗的GEP-NENs患者EDR值衰减规律进行拟合分析,旨在为患者出院时机建立指南并为出院后公众辐射防护提供建议。
研究设计与样本
- 研究纳入30例接受[177Lu]Lu-DOTA-TATE治疗的GEP-NENs患者,测量注射期间及给药后0-6 h的EDR值以及对护士和周围环境的RD值。
- 采用双指数曲线拟合,估算不同出院时间对公众的RD。
主要发现
- 30例患者中27例完成4周期[177Lu]Lu-DOTA-TATE治疗。
- 估算对公众的RD显示,成人家庭成员、10岁以上儿童、3-10岁儿童及同事分别在注射后至少24 h、48 h、144 h和192 h开始日常接触,可确保4次治疗后总RD值不超过限值。
- 住院期间给药护士和病房环境累积剂量均远低于国家RD限值。
临床怎么用
- 作者建议患者出院后与成人家庭成员、10岁以上儿童、3-10岁儿童及同事开始日常接触的最短时间分别为注射后至少24 h、48 h、144 h和192 h,以确保4次治疗后总RD值不超过限值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We conducted a study on radiation exposure in patients with gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) treated with [177Lu]Lu-DOTA-TATE in China for the first time, aiming to provide guidance and reference for radiation protection in this regard. A total of 30 GEP-NENs patients who received [177Lu]Lu-DOTA-TATE therapy were recruited in the study. We measured the external dose rate (EDR) values of each patient during the injection and 0-6 h post-administration period, as well as the radiation dose (RD) values to healthcare nurses and the surrounding environment. We performed a double exponential curve fitting and estimated the RD to the public from patients discharged at different times after [177Lu]Lu-DOTA-TATE therapy. RESULTS: Among the 30 patients, 27 patients completed 4 cycles of [177Lu]Lu-DOTA-TATE treatments, the estimated RD to the public indicated that for adult family members, children above 10 years old, children aged 3-10 and coworkers of the patients, patients could begin daily contact at least 24 h, 48 h, 144 h and 192 h after injection to ensure that the total RD values after four treatments not exceed the limit. During the hospitalization of patients receiving [177Lu]Lu-DOTA-TATE, the cumulative dose received by the administering nurses and to the ward environment were both well below the national RD limits. CONCLUSIONS: This study conducted a fitting analysis of the decay pattern of EDR values in GEP-NENs patients undergoing [177Lu]Lu-DOTA-TATE therapy, in order to establish guidelines for patient discharge timing and provide recommendations for radiation protection for the general public after patient discharge. Trial registration A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs, NCT05459844. https://clinicaltrials.gov/study/NCT05459844?cond=NCT05459844&rank=1 . Registered 5 July 2022.
引用
- Liu F, Li P, Xu J, et al. Radiation exposure and protection advice after [177Lu]Lu-DOTA-TATE therapy in China. EJNMMI Res. 2024. PMID: 39607652. doi:10.1186/s13550-024-01185-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。